Register
Login

Trending Topic

abstract blue eye
8 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

On 28 May 2024, enrolment in phase III clinical trials for sozinibercept in neovascular age-related macular degeneration (nAMD) was completed.1 These trials include two large multicentre, double-masked, randomized controlled trials (RCTs): COAST (OPT-302 with aflibercept in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757636) and ShORe (OPT-302 with ranibizumab in neovascular age-related macular degeneration; ClinicalTrials.gov identifier: NCT04757610).2,3 These trials represent one of the largest phase […]

< 1 min

The Role of Optical Coherence Tomography in the Diagnosis of Early Age-related Maculopathy

Ling Zhi Heng, Sobha Sivaprasad
Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Published Online: Jan 23rd 2013 European Ophthalmic Review, 2012;6(5):255-260 DOI: http://doi.org/10.17925/EOR.2012.06.05.255
Select a Section…
1

Abstract

Overview

There has been increasing interest in improving imaging technologies to identify and grade early age-related maculopathy (ARM).
Recently, advances in optical coherence tomography (OCT) has allowed a virtual biopsy of the retina and identification of different types of drusen in relation to early ARM. Several investigators have improved our understanding of both the qualitative and quantitative analyses of drusen, the clinical hallmark of ARM. The purpose of this article is to critically review the current literature inOCT in the evaluation of early ARM. Although seemingly useful and ideal, the current analysis of the retina using OCT is highly complex and lacking. It is currently too premature to use OCT as a grading tool for early ARM. However, the authors are hopeful that the rapid progress in this field will enable the use of an OCT-defined outcome measure in early ARM clinical trials in the foreseeable future.

2

Article

To view the full article in PDF or eBook formats, please click on the icons above.

3

Further Resources

Share
Facebook
X (formerly Twitter)
LinkedIn
Via Email
Mark CompleteCompleted
BookmarkBookmarked
Copy LinkLink Copied
Download as PDF
Close Popup